Reuters logo
BRIEF-Camurus and Braeburn Pharma announce phase 2 results for long-acting Buprenorphine in opioid dependent patients with chronic pain
July 12, 2017 / 6:11 PM / 4 months ago

BRIEF-Camurus and Braeburn Pharma announce phase 2 results for long-acting Buprenorphine in opioid dependent patients with chronic pain

July 12 (Reuters) - Camurus Ab

* Camurus and Braeburn Pharmaceuticals announce topline phase 2 results for long-acting buprenorphine in opioid dependent patients with chronic pain

* Camurus ab says as in previous clinical studies, CAM2038 was shown to be well tolerated Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below